This two-year Phase II grant, awarded through the Small Business Innovation Research (SBIR) program of the National Science Foundation, will support studies focused on the synthesis and testing of the company’s lead antibiotic, MU1140. Successful development of DPOLT will enable, for the first time, large-scale commercial production of MU1140 and other related antibiotics, which the company believes will be effective in treating some of the most troublesome human infections.